top of page

PureFlowCath Catheter 

The Company is developing PureFlowCath Catheter, the first urinary catheter system to provide continuous irrigation (CSCI) with the objective of reducing urinary tract infections .

Capital provided to date      US$ 8.35 million
Patents awarded including EU
Patents securitised in Luxembourg
Prospectus for admission to Toronto Stock
Exchange Venture advanced

Global sales 2023  US$         794,001,774
Projected annual growth      5.72 %           

Income Royalty Rate Report 

Market Demand

The Company following it's regulated listing on a designated stock exchange will enter into new  inovative medical device opportunities.

Providing funding and support to medical practitioner's to advance new medical device innovations to market.

bottom of page